Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Technical Presentation (July 2024)

27 slides from Vivoryon Therapeutics's technical presentation, Jul 18, 2024

  1. Slide 1: R&D Update Call: Unique treatment effect of varoglutamstat on kidney function in diabetes patients

    R&D Update Call: Unique treatment effect of varoglutamstat on kidney function in diabetes patients July 18, 2024 |Vivoryon Therapeutics N.V.

  2. Slide 2: Important Notice and Disclaimer

    Important Notice and Disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment

  3. Slide 3: Entering a new era of R&D focused on kidney disorder therapies

    Entering a new era of R&D focused on kidney disorder therapies Significant kidney function improvement (total VIVIAD population) P Statistically significant and clinically meaningful change in eGFR1 in overall VIVIAD Phase 2 study population (prespecified analysis) • Between-group treatment effect o

  4. Slide 4: Enhanced kidney function in diabetes patients

    Enhanced kidney function in diabetes patients Compelling outcomes in diabetes subgroup of VIVIAD study Compelling outcomes in diabetes Clear pathway to advance in DKD P Treatment effect in diabetes subgroup1 was substantially ◆ Complement available data with a higher than in the overall patient popu

  5. Slide 5: VIVIAD Study - Kidney Data

    VIVIAD STUDY - KIDNEY DATA All patient analysis and diabetes subgroup analysis

  6. Slide 6: Kidney function was investigated as part of VIVIAD Phase 2b

    Kidney function was investigated as part of VIVIAD Phase 2b Study included prospectively specified endpoint to evaluate kidney function in elderly AD patients Patients1: Mild cognitive impairment Initial 1:1:1 randomization2 Randomization after patient 90 or mild dementia (early Alzheimer’s DSMB Jun

  7. Slide 7: VIVIAD Phase 2b baseline characteristics

    VIVIAD Phase 2b baseline characteristics Total population and diabetes subgroup 1 1 Key figures ◆ Average age > 68 years ◆ Diabetes subgroup ≈ 12% of VIVIAD patients ◆ Mean baseline eGFR ≈ 80 mL/min/1.73m^2 2 1 Diabetes subgroup defined as defined as patients having at baseline either medical histor

  8. Slide 8: Baseline medication in varoglutamstat arm of VIVIAD Phase 2b

    Baseline medication in varoglutamstat arm of VIVIAD Phase 2b Diabetes patients received multiple SoC therapies for diabetes and hypertension Diabetes-specific medication Other medication Diabetes subgroup 100% Diabetes subgroup 100% 80% 80% 75% 65% 60% 60% 60% 40% 40% 40% 35% 25% 20% 20% 15% 15% 20%

  9. Slide 9: Treatment effect even more evident in diabetes subgroup

    Treatment effect even more evident in diabetes subgroup eGFR measured using creatinine and MDRD All subjects (n=258) Diabetes (n=32) Placebo n= 117 Varo n=141 Placebo n=12 Varo n=20 9 8 Statistically significant (varoglutamstat vs. placebo) improvement in annualized 7 eGFR treatment effect change in

  10. Slide 10: Treatment effect seen across methodologies

    Treatment effect seen across methodologies Measurement of eGFR using all cystatin C measurements and 2021 CKD-EPI All subjects (n=258) Diabetes (n=32) Placebo n= 117 Varo n=141 Placebo n=12 Varo n=20 6 5 Statistically significant (varoglutamstat vs. placebo) improvement in annualized eGFR treatment

  11. Slide 11: Time analysis shows durable treatment effect over two years

    Time analysis shows durable treatment effect over two years Up to nine-month escalation period before reaching full treatment effect Diabetes Change in eGFR over time (MDRD) eGFR (mL/min/1.73m^2) Onset of action: ◆ First treatment effect seen at week 24, approx. 50% of maximum effect observed Sustai

  12. Slide 12: Excellent safety profile consistent across 2 years study duration

    Excellent safety profile consistent across 2 years study duration Varoglutamstat was well-tolerated at the dose of 600mg BID VIVIAD total population Diabetes subgroup3 (total N = 259) (total N = 32) Varoglutamstat Placebo Varoglutamstat Placebo Item N (%)1 N (%)1 N (%)1 N (%)1 Patients randomized 14

  13. Slide 13: No adverse kidney effects observed

    No adverse kidney effects observed No meaningful differences observed in renal and metabolic systems AE in total population and diabetes subgroup Number of patients with TEAEs by system organ class (SOC)1 7Infections and infestations 7 Infections and infestations 6 Infections and infestations 9 Gast

  14. Slide 14: Urine dipstick analysis showed no evidence of increased proteinuria

    Urine dipstick analysis showed no evidence of increased proteinuria VIVIAD (all) and diabetes subgroup shows varoglutamstat has no adverse effect on kidney 100% 90% Majority of trial participants had no Clear evidence that varoglutamstat does not induce or increase 80% proteinuria through all time p

  15. Slide 15: Additional health benefits observed in diabetes subgroup

    Additional health benefits observed in diabetes subgroup Promising effects on weight loss, blood pressure and liver enzymes Change in weight from Change in diastolic Change in liver transaminases from baseline (kg) blood pressure from baseline (IU/L) baseline (mmHg) Weight Diastolic Blood Pressure A

  16. Slide 16: Reduction of inflammation likely contributing to treatment effect

    Reduction of inflammation likely contributing to treatment effect No change in glycemic control; change in pE-CCL2 provides insight into mechanism of action Positive effect on kidney function appears Reduction in pE-CCL2 – a marker of independent of any change in glycemic control inflammation – with

  17. Slide 17: Varoglutamstat in DKD

    VAROGLUTAMSTAT IN DKD Proposed Development Plan

  18. Slide 18: Addressing unmet needs in diabetic kidney disease (DKD)

    Addressing unmet needs in diabetic kidney disease (DKD) DKD is one of the leading causes of CKD and end stage renal disease (ESRD) globally Diabetes is a significant and Diabetic kidney disease (DKD) is growing global challenge defined by the presence of chronic kidney (adults aged 20-79 years with

  19. Slide 19: Effect of varoglutamstat on kidney function has a unique profile

    Effect of varoglutamstat on kidney function has a unique profile SGLTi eGFR (compiled)4 Varoglutamstat’s effect on annualized eGFR slope is unique when compared to other drug classes used in DKD SGLT2 GLP-1 QPCT/L Canagliflozin Dapagliflozin Semaglutide Varoglutamstat CREDENCE1 DAPA-CKD2 FLOW3 VIVIA

  20. Slide 20: Outstanding data in VIVIAD diabetes subgroup informs next steps

    Outstanding data in VIVIAD diabetes subgroup informs next steps Phase 2 study planned in more advanced patients to enable robust Phase 3 planning for DKD VIVIAD results by baseline eGFR severity Varoglutamstat annualized change of eGFR versus placebo (total population) 5 varoglutamstat vs. placebo m

  21. Slide 21: Next steps for varoglutamstat development: Phase 2

    Next steps for varoglutamstat development: Phase 2 Proposed Phase 2 study1 in people with DKD as initial target in kidney disease Draft design ◆ Stage 3b/4 DKD patients with > 100mg/g albuminuria / Key endpoints proteinuria Up to 120 patients treated for 15 months to ◆ eGFR slope ◆ All patients on s

  22. Slide 22: Potential future opportunities include orphan diseases

    Potential future opportunities include orphan diseases Varoglutamstat potential in orphan diseases with major risk for end stage renal disease – e.g. Alport Syndrome / Fabry Disease No specific treatment for progression to kidney failure available; current therapies slow down progression Need ◆ but

  23. Slide 23: Evidence supports QPCT/L inhibitors improving inflammation/fibrosis

    Evidence supports QPCT/L inhibitors improving inflammation/fibrosis Over a decade of research showing clear effects in glomerulonephritis (kidney) and NAFLD (liver) Persistent low-grade inflammation is now considered a Novel research activities initiated: hallmark feature of chronic kidney disease (

  24. Slide 24: Experts support all aspects of kidney disease strategy

    Experts support all aspects of kidney disease strategy Collaborating with medical advisors and industry leaders to further shape our strategic shift towards inflammatory/fibrotic diseases including kidney disease Tobias B. Huber, MD Florian Jehle Kevin Carroll, PhD Chair of the Center of Internal CE

  25. Slide 25: Varoglutamstat has the potential to be the first oral treatment improving kidney function

    Varoglutamstat has the potential to be the first oral treatment specifically aimed at improving kidney function on top of SoC Compelling efficacy and safety data in people at risk of kidney disease ü Statistically significant effect on kidney function in total VIVIAD population and diabetes subgroup

  26. Slide 26: Q&A

    Q&A

  27. Slide 27: Vivoryon Therapeutics N.V.

    VIVORYON THERAPEUTICS N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — Technical Presentation (July 2024) on 6ix